Cargando…
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
BACKGROUND: Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cel...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844985/ https://www.ncbi.nlm.nih.gov/pubmed/33514411 http://dx.doi.org/10.1186/s13287-021-02147-6 |
_version_ | 1783644466221940736 |
---|---|
author | Nagpal, Anjali Milton, Austin G. Koblar, Simon A. Hamilton-Bruce, M. Anne |
author_facet | Nagpal, Anjali Milton, Austin G. Koblar, Simon A. Hamilton-Bruce, M. Anne |
author_sort | Nagpal, Anjali |
collection | PubMed |
description | BACKGROUND: Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. METHODS: We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. RESULTS: The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. CONCLUSIONS: The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02147-6. |
format | Online Article Text |
id | pubmed-7844985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78449852021-02-01 Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products Nagpal, Anjali Milton, Austin G. Koblar, Simon A. Hamilton-Bruce, M. Anne Stem Cell Res Ther Method BACKGROUND: Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. METHODS: We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. RESULTS: The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. CONCLUSIONS: The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02147-6. BioMed Central 2021-01-29 /pmc/articles/PMC7844985/ /pubmed/33514411 http://dx.doi.org/10.1186/s13287-021-02147-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Method Nagpal, Anjali Milton, Austin G. Koblar, Simon A. Hamilton-Bruce, M. Anne Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title | Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_full | Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_fullStr | Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_full_unstemmed | Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_short | Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_sort | clinical translation of cell therapies in stroke (ct2s) checklist—a pragmatic tool to accelerate development of cell therapy products |
topic | Method |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844985/ https://www.ncbi.nlm.nih.gov/pubmed/33514411 http://dx.doi.org/10.1186/s13287-021-02147-6 |
work_keys_str_mv | AT nagpalanjali clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT miltonausting clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT koblarsimona clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT hamiltonbrucemanne clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts |